Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Google Secures Pentagon AI Deal for Classified Projects 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
MONTROUGE, France, Feb. 8, 2016 -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that Charles Ruban, Chief Commercial Officer, and Susanna Mesa, Vice President of Finance, Investor Relations & Strategy, will present at LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10th, 2016 at
3:55 pm ET at the Waldorf Astoria Hotel in New York, NY.
A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website, http://www.dbv-technologies.com/en/investor-relations. A replay will also be available 48 hours after the event.
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation and Breakthrough Therapy designation from the U.S. Food and Drug Administration.
About DBV Technologies
DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
| DBV Technologies Contacts | |
|
Nathalie Donne Director, Corporate Communication & Business Development Tel. : +33 (0)1 55 42 78 72 [email protected] |
Susanna Mesa VP of Finance, Investor Relations & Strategy Tel. : +1 212-271-0861 [email protected] |
|
DBV Technologies Media Contacts US & Europe |
|
|
Marion Janic Rooney & Associates Tel. : +1 212-223-4017 [email protected] |
Caroline Carmagnol Alize RP - Relation Presse Tel. : +33 (0)6 64 18 99 59 [email protected] |
PDF Version http://hugin.info/156437/R/1984165/727364.pdf
HUG#1984165
